- Alle
- Pressemitteilungen
- Empfehlungen
- Chartanalysen
- Berichte
| Zeit | Aktuelle Nachrichten Sprache:
Alle DE EN | Leser | Medien | ||
|---|---|---|---|---|---|
| CIVITAS SOLUTIONS Aktie jetzt für 0€ handeln |
0 Nachrichten in den letzten 12 Monaten
| Unternehmen / Aktien | Aktienkurs | % | Top-Nachrichten | ||
|---|---|---|---|---|---|
| GERRESHEIMER | 19,460 | +1,88 % | Shortseller-Positionen aktuell: Auto1, Delivery Hero, freenet, Gerresheimer, Hypoport, Nagarro, Suss MicroTec | Wer Aktien leerverkauft, also auf fallende Kurse spekuliert (Shortselling), unterliegt bestimmten Transparenzpflichten. Aktuelle Meldungen über Leerverkäufe geben Aufschluss darüber. Diese Vorgaben... ► Artikel lesen | |
| DEXCOM | 59,37 | +0,46 % | Analysts outline future catalysts for Dexcom with 15-Day CGM, potential reimbursement wins | ||
| PLUS THERAPEUTICS | 0,299 | 0,00 % | Plus Therapeutics Inc.: Plus Therapeutics Announces New Category III CPT Code for Convection-Enhanced Delivery Used with REYOBIQ | HOUSTON, Feb. 25, 2026 (GLOBE NEWSWIRE) -- Plus Therapeutics, Inc. (NASDAQ: PSTV) (the "Company"), a healthcare company developing and commercializing precision diagnostics and radiopharmaceuticals... ► Artikel lesen | |
| CARDINAL HEALTH | 191,40 | -0,08 % | Leerink Partners bekräftigt Outperform-Rating für Cardinal Health | ||
| DAVITA | 130,55 | -0,72 % | DaVita tops chart as the only large-cap healthcare services name rated Strong Buy | ||
| EVOFEM BIOSCIENCES | - | - | Evofem Biosciences, Inc.: Evofem Reports Financial Results for Third Quarter of 2025, Provides Business Update | -- Increased Net Sales 10% While Lowering Operating Expenses 42% vs. Prior Year Quarter --
-- Delivered $1.0 Million of Operating Income in Q3 2025 --
SAN DIEGO... ► Artikel lesen | |
| DENTSPLY SIRONA | 11,050 | -0,72 % | Dentsply Sirona: First-ever Dental Dedicated MRI System Validated In Trial, Cleared By FDA | BRUSSELS/FRANKFURT/PARIS (dpa-AFX) - Dentsply Sirona (XRAY) and Siemens Healthineers (SHL.DE) announced that the dental-dedicated ddMRI system - MAGNETOM Free.Max Dental Edition - has received... ► Artikel lesen | |
| CENTENE | 37,245 | -0,15 % | Centene to reaffirm full-year earnings guidance | ||
| CYTOSORBENTS | 0,738 | +7,58 % | Cytosorbents Corp: CytoSorbents Reports Preliminary Unaudited Fourth Quarter and Full-Year 2025 Results and Business Update | Fourth quarter and Full-Year 2025 revenue are expected to be approximately $9.2 million and $37.0 million, respectively, with expected Q4 gross margins in the range... ► Artikel lesen | |
| COOPER COMPANIES | 65,00 | -0,76 % | The Cooper Companies, Inc. Q1 Income Advances | WASHINGTON (dpa-AFX) - The Cooper Companies, Inc. (COO) released a profit for its first quarter that Increases, from last yearThe company's earnings totaled $130.8 million, or $0.66 per share.... ► Artikel lesen | |
| EKSO BIONICS | 11,980 | 0,00 % | Applied Digital Corporation: Applied Digital to Spin Out Cloud Business, Proposes Business Combination with EKSO to Launch ChronoScale | DALLAS, Dec. 29, 2025 (GLOBE NEWSWIRE) -- Applied Digital (NASDAQ: APLD), a designer, builder, and operator of high-performance, sustainably engineered data centers and colocation services for artificial... ► Artikel lesen | |
| FULGENT GENETICS | 12,800 | -0,78 % | Fulgent Genetics forecasts $350M 2026 revenue and 53% AP growth as Bako, StrataDx acquisitions reshape customer mix | ||
| IMUNON | 2,680 | -3,60 % | Imunon, Inc.: IMUNON Reports Third Quarter 2025 Financial Results and Provides Business Update | R&D Day showcased remarkable Investigator optimism, continued strengthening supportive data, and significant progress with Phase 3 OVATION 3 Study in pursuit of first frontline immunotherapy for advanced... ► Artikel lesen | |
| DELCATH SYSTEMS | 7,750 | -1,27 % | Delcath Systems, Inc.: Delcath Systems Announces Investigator-Initiated CHOPIN Phase 2 Trial Presentation at ESMO 2025 Congress | Delcath Systems, Inc. (NASDAQ: DCTH), an interventional oncology company focused on the treatment of primary and metastatic liver cancers, today announced the acceptance of an oral presentation on... ► Artikel lesen | |
| CAREDX | 15,060 | -0,20 % | CareDx skizziert Wachstumsstrategie: Expansion in der Transplantationsmedizin und Onkologie |
Das Unternehmen CIVITAS SOLUTIONS INC kann der Branche Gesundheitswesen zugeordnet werden.
Sie erhalten auf FinanzNachrichten.de kostenlose Realtime-Aktienkurse von und sowie Kurse und Daten von ARIVA.DE AG.
Weitere Kennzahlen, Fundamentaldaten und Unternehmensinformationen zu CIVITAS SOLUTIONS INC finden Sie auf Wallstreet Online.